Non-small cell lung cancer
Not yet recruitingSafety and efficacy of Rilvegostomig with drug combination in adult patients with unresectable stage III non‑small cell lung cancer undergoing chemoradiotherapy
Safety and efficacy of Rilvegostomig with drug combination in adult patients with unresectable stage III non‑small cell lung cancer undergoing chemoradiotherapy
- Disease:Non-small cell lung cancer
- Substances:CarboplatinCisplatin+5
Spain- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:AstraZeneca AB








